中联品牌怎么样 申请店铺

我要投票 中联在医疗器械行业中的票数:70 更新时间:2025-01-18
中联是哪个国家的品牌?「中联」是 国药集团中联药业有限公司 旗下著名品牌。该品牌发源于湖北省武汉市,由创始人蒋焘在1998-04-09期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
中联怎么样

国药中联有着悠久的历史,由拥有四百余年中医药历史并享誉全国的叶开泰、达仁堂、刘有余堂金同仁、九芝堂、陈太乙等为代表的192家中药店铺联合组建而成。1952年,在原武汉市中药饮片业同业公会的发动下,成立武汉市中联制药厂。1997年股份制改造,2002年成立集团公司,2011年底重组进入中国较大的健康产业平台――中国医药集团。经过60余年发展壮大,公司已形成包括中成药、化学制剂生产和销售、医药商业营运等在内的多种产业结构,成为集科研、生产、流通、外贸于一体的专业医药健康企业。

公司专注经典中药生产与销售。拥有注册产品300余个,有82个品种列入国家基本药物目录,有14个品种,其中战略大品种鳖甲煎丸有两千多年历史,为汉代张仲景经典古方,专治胁下癥块。公司产品涉足肝脏用药、呼吸系统用药、妇科用药、心脑血管用药等特色领域,已形成以鳖甲煎丸为代表的肝脏用药系列,以金叶败毒颗粒、鼻炎片、强力感冒片为代表的呼吸道用药系列,以脉君安片、心脑清软胶囊为代表的心脑血管用药系列,以加味生化颗粒为代表的妇科用药系列。

公司注重经典中药的系统深度开发。依托国药集团旗下中国医药工业研究总院研发平台,广泛开展国内、国际合作与交流,不断探索经典古方治病机理,研究新工艺,保障产品疗效,拥有多项自主知识产权,为公司的可持续发展奠定了坚实地基础。

公司营销网络遍布全国多省、自治区、直辖市,终端销售网点覆盖全国,主要品种出口日本、马来西亚、印尼、美国等国家和地区。公司不仅销售产品,同时专注于将中医药哲学(文化)、产品核心价值传递给医生和患者,使“中联”成为受医生和患者尊重的制药企业,为中国中医药的发展贡献力量。

公司在东湖高新技术开发区光谷生物城按照现代中药生产标准兴建的“中联中医药产业园”已经建成,未来,公司将以此为依托,以“挖掘传承创新发扬中国中药,为‘家人’提供经典好中药”为已任,传承发扬中国中药,力争成为国内优秀现代化中药企业。十三五末营业收入过十亿元,利润过亿元。


Sinopharm has a long history. It is composed of 192 traditional Chinese medicine stores represented by Ye Kaitai, Da Rentang, Liu youyutang, Jin Tongren, Jiuzhitang and Chen Taiyi, who have more than 400 years of traditional Chinese medicine history and are well-known throughout the country. In 1952, Wuhan Zhonglian pharmaceutical factory was established under the initiative of the former Wuhan herbal medicine industry association. In 1997, the joint-stock system was reformed, and the group company was established in 2002. At the end of 2011, it was reorganized into China's larger health industry platform, China Pharmaceutical Group. After more than 60 years of development and expansion, the company has formed a variety of industrial structures, including the production and sales of Chinese patent medicine, chemical preparations, pharmaceutical commercial operation, etc., and has become a professional pharmaceutical health enterprise integrating scientific research, production, circulation and foreign trade. The company focuses on the production and sales of classic Chinese medicine. There are more than 300 registered products, 82 varieties are listed in the national basic drug catalog, and 14 varieties, of which the strategic big variety Biejiajian Pill has a history of more than 2000 years. It is a classic ancient recipe of Zhang Zhongjing in Han Dynasty and specializes in treating hypochondriac diseases. The company's products are involved in the fields of liver medicine, respiratory system medicine, gynecology medicine, cardio cerebral vascular medicine, etc. it has formed a series of liver medicine represented by Biejiajian Pill, respiratory medicine represented by Jinyebaidu granule, Biyan tablet, qiangliganmao tablet, cardio cerebral vascular medicine represented by maijunan tablet and xinnaoqing soft capsule, and Jiawei biochemical granule The representative series of gynecological medicine. The company pays attention to the systematic and in-depth development of traditional Chinese medicine. Relying on the R & D platform of China Pharmaceutical Industry Research Institute under Sinopharm group, the company has extensively carried out domestic and international cooperation and exchanges, constantly explored the mechanism of classical ancient prescriptions, studied new technologies, guaranteed the product efficacy, and possessed a number of independent intellectual property rights, laying a solid foundation for the company's sustainable development. The company's marketing network covers many provinces, autonomous regions and municipalities directly under the central government, and the terminal sales outlets cover the whole country. The main products are exported to Japan, Malaysia, Indonesia, the United States and other countries and regions. The company not only sells products, but also focuses on delivering the Philosophy (Culture) and core values of traditional Chinese medicine to doctors and patients, making Zoomlion a pharmaceutical enterprise respected by doctors and patients and contributing to the development of traditional Chinese medicine in China. The "Zhonglian traditional Chinese medicine industrial park" built by the company in the Guanggu biological city of Donghu high tech Development Zone in accordance with the production standards of modern traditional Chinese medicine has been completed. In the future, the company will take this as the support, take "mining, inheriting, innovating and carrying forward Chinese traditional medicine, providing classic and good traditional Chinese medicine for" family "as the responsibility, inherit and carry forward Chinese traditional medicine, and strive to become an excellent modern Chinese medicine enterprise in China. At the end of the 13th five year plan, the operating revenue was over one billion yuan and the profit was over one billion yuan.

本文链接: https://brand.waitui.com/9f77d79a5.html 联系电话:027819389818805

千城特选小程序码

7×24h 快讯

兆龙互连:预计未来800G、1.6T高速率产品市场需求量会持续增加

兆龙互连(300913)近日接受机构调研时表示,行业景气度在持续提升,运用端需求旺盛,各主要厂家也在推进产品的更新迭代,预计未来800G、1.6T高速率产品市场需求量会持续增加。为积极顺应市场对更高速率产品高性能的要求,公司将持续加大研发投入,推动技术创新与产品迭代升级,积极抢占市场份额。(证券时报)

2小时前

第三届链博会海外路演活动将于本月启动 首站将设在泰国

中国贸促会昨天举办发布会,对外发布了第三届中国国际供应链促进博览会的筹备工作情况。第三届链博会的各项工作正在有序推进,目前已有近70家中外知名企业签约参展。第三届链博会产业链供应链国际合作的特色更加突出。同时,第三届链博会海外路演活动也即将于本月启动,首站将设在泰国。(财联社)

2小时前

浙江进出口规模首次突破5万亿元

从1月17日举行的杭州海关新闻通气会上获悉,2024年,浙江进出口规模首次突破5万亿元大关,占全国份额达12.0%;出口增速达9.5%,继2023年后再次居东部沿海主要省市首位。 (财联社)

2小时前

商务部副部长一行赴北京喜隆多店调研指导永辉超市调改工作

1月17日,商务部党组成员、副部长盛秋平带队调研北京永辉超市喜隆多店,商务部流通发展司、北京市商务局、石景山区政府相关人员及永辉超市首席执行官李松峰陪同调研。盛秋平对永辉超市的调改工作高度肯定。他表示,永辉超市的调改回归了零售本质,为消费者提供货真价实、优质优价的商品和服务。他也提出,永辉超市要继续坚持调改标准,进一步强化供应链系统,精益求精,不断优化管理水平,推动零售业的创新提升,为惠民生和促消费作出更大贡献。(证券时报)

2小时前

云南:全省初一在校女生可免费接种国产HPV疫苗

2025年云南省政府工作报告把实施“儿童健康护佑和生物疫苗惠民工程”列为2025年要办的10件惠民实事之一,明确提出建设1个具有儿童(含新生儿)重症救治Ⅲ级水平的省级儿童医学救治中心,5个具有Ⅱ级水平的州(市)级儿童急诊或重症学科,70个具有Ⅰ级及以上水平的县级儿童急救点,建立覆盖全省的儿童救治网络;按照知情、自愿原则,为全省符合条件的初一在校女生免费接种国产HPV疫苗。(财联社)

2小时前

本页详细列出关于伟思VISHEE的品牌信息,含品牌所属公司介绍,伟思VISHEE所处行业的品牌地位及优势。
咨询